Complications and clinical outcomes of retroperitoneal lymph node dissection for testicular cancer in a centralized population-based cohort in Sweden: insights from SWENOTECA
OBJECTIVE: Retroperitoneal lymph node dissection (RPLND) for testicular germ cell cancer is a complex procedure associated with postoperative complications and long-term morbidity, best performed by experienced surgeons at high-volume centers. This study evaluates surgical outcomes of RPLND in a centralized population-based cohort. METHODS: This is a retrospective analysis of a prospective multicenter cohort of all RPLNDs in Sweden between 2018 and 2022. 217 patients (175 nonseminomas and 42 seminomas) underwent unilateral or bilateral primary RPLND or post-chemotherapy RPLND. Primary outcomes were complications, loss of ejaculation, and histopathology. RESULTS: Intraoperative complications occurred in 8% of unilateral and 0% of bilateral templates in primary RPLND, and in 0 and 8% in post-chemotherapy RPLND, most commonly renal injury. Postoperative complications rate was significantly higher with bilateral templates in post-chemotherapy RPLND (49% vs 18%, p < 0.01). Clavien-Dindo ≥ IIIb complications occurred in 2 (primary) and 3% (post-chemotherapy), respectively. Loss of ejaculation was numerically more common after bilateral templates (primary: 60% vs 31%, p = 0.07; post-chemotherapy: 53% vs 38%, p = 0.09). Viable cancer was found in 95% of seminomas and 52% of nonseminomas for primary RPLND and in nonseminoma post-chemotherapy RPLND, 11% viable cancer, 50% teratoma, and 39% benign nodes. Robotic surgery did not increase complications or loss of ejaculation. CONCLUSIONS: RPLND demonstrated low complication rates and rare serious events. Bilateral templates were associated with increased loss of ejaculation. Robotic surgery was safe, and prior chemotherapy did not preclude laparoscopy. Post-chemotherapy RPLND showed more teratoma and viable cancer, and fewer benign findings than previously reported.
Authors
- Anna Thor (ORCID: https://orcid.org/0000-0003-2915-1761)
- Anna K Jansson (ORCID: https://orcid.org/0000-0001-6305-9729)
- Per‐Olof Lundgren (ORCID: https://orcid.org/0000-0001-7976-6962)
- Anders Kjellman (ORCID: https://orcid.org/0000-0002-9080-9027)
- Anna Grenabo Bergdahl (ORCID: https://orcid.org/0000-0003-3266-7611)
- Ingrid Cecilia Glimelius (ORCID: https://orcid.org/0000-0001-6158-3041)
- Torgrim Tandstad (ORCID: https://orcid.org/0000-0002-9786-2138)
- Berglind Johannsdottir
- Gabriella Cohn‐Cedermark (ORCID: https://orcid.org/0000-0002-5681-5829)
- Axel Gerdtsson (ORCID: https://orcid.org/0000-0003-4033-5078)
- Martin Hellström
- Armin Abniki
Institutions
- Uppsala University (SE)
- Karolinska University Hospital (SE)
- Malmö University (SE)
- Norwegian University of Science and Technology (NO)
- Sahlgrenska University Hospital (SE)
- Karolinska Institutet (SE)
- St Olav's University Hospital (NO)
- Skåne University Hospital (SE)
- Umeå University (SE)
Publication Details
- Journal
- Scandinavian Journal of Urology
- Published
- 2026-04-13
- DOI
- https://doi.org/10.2340/sju.v61.45743
- Primary Topic
- Testicular diseases and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00